Readjustment of R & D pattern of pharmaceutical enterprises and operation focus of foreign enterprises

Recently, the news that Novartis China will close its early R & D center attracted wide attention However, Novartis China stated that it was only adjusting its operation focus, and then focused on expanding the scale and field of early clinical development and later clinical trials In fact, in recent years, multinational pharmaceutical companies are closing down China's R & D center in succession As early as 2015, Alberta closed the kidney disease R & D center; Novartis dissolved China's biological R & D department in 2016, Roche also reduced China's biological R & D team; in 2017, global pharmaceutical companies such as GlaxoSmithKline and Lilly announced the removal of China's R & D center in succession On the contrary, AstraZeneca announced plans to double the number of employees in its Shanghai R & D base and set up a $1 billion investment fund to continuously increase investment in China First of all, due to the change of domestic drug marketing logic With the continuous optimization of drug examination process, acceleration of innovative drug examination and approval, and continuous improvement of innovation initiative of enterprises, it is inevitable for multinational pharmaceutical enterprises to eliminate backward production capacity and increase investment in new products Second, the rising cost of R & D is another reason why foreign pharmaceutical companies choose to close their own R & D centers Especially in the talent and transnational management costs, the global drug R & D trend began to change from inward R & D to collaborative R & D, and the Chinese market is no exception Outsourcing R & d rather than fully internal R & D has become the choice of multinational drug companies Finally, the listing permit holder system is being actively implemented throughout the country In 2015, the State Council issued the opinions on reforming the review and approval system of medical devices, which opened the curtain of deepening the reform of China's drug regulatory system; in 2016, the pilot work of listing license holders was officially launched; in August 2017, Beijing, Tianjin, Hebei, Shanghai and other 10 pilot areas of drug listing license holders system; on September 13, 2017, Shanghai took the lead in launching the listing license of medical devices Pilot holder system New R & D mode is spreading The listing permit holder system can release the vitality of local drug research and development, and improve the efficiency of drug research and development and production Drug R & D enterprises can entrust R & D to cro (contract research organization) enterprises and production to CMO (contract manufacturing organization) enterprises without their own laboratories or factories Under the background that the government encourages new drug research and development, Chinese cro and CMO enterprises will usher in more development opportunities and gain more market share According to the report "development trends of pharmaceutical R & D outsourcing in Asia" released by PricewaterhouseCoopers, considering cost, risk and market opportunity, China has replaced India as the most popular pharmaceutical outsourcing service country in Asia At the same time, a number of domestic cro / CMO enterprises have also planned to go public.